Company’s lead candidate ENV-105 has been selected as winner of the Cancer Immunology Solution of the Year Award
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company targeting drug resistance
Houston conference serves as a platform devoted to advancing the field of basic, preclinical, and translational cancer research
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common
Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused
Zero Grade 3+ Toxicities associated with ENV-105 in 13 Patients; ENV-105 (Carotuximab) Demonstrates Clean Safety Profile in Combination with Osimertinib (AstraZeneca's Tagrisso®) — Advancing Kairos's Mission to
Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides a mid-year update for 2026 and a look ahead to the rest of the year in a letter to
Company selected for the Leaders in Drug Resistance Development award
Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that its Annual Meeting of Shareholders will be held virtually at 9:00 am PDT on Monday,
LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kairos Pharma, Ltd. ("Kairos" or
Company selected as an Emerald honoree for Innovator of Biotech Solutions
Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE:KAPA) resulting from allegations that Kairos
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Kairos Pharma, Ltd. (NYSE:KAPA) resulting from allegations that Kairos
